2022 World Conference on Lung Cancer (ePosters)-EP08.02-166. Brain Metastases in Patients with ALKrearranged or ROS1-fusion Non-small-Cell Lung Cancers in China

EP08.02-166. Brain Metastases in Patients with ALKrearranged or ROS1-fusion Non-small-Cell Lung Cancers in China

Pdf Summary

The study evaluated the frequency of brain metastases (BM) in patients with ALK-rearranged or ROS1-fusion non-small-cell lung cancer (NSCLC) in China. The results showed that BM were present in 19.6% of ALK-rearranged and 11.1% of ROS1-fusion NSCLCs at the time of diagnosis of advanced disease. There was no difference in the cumulative incidence of BM over time between the two cohorts. In still living patients with advanced ALK-rearranged NSCLC, the incidence of BM was 12.8% at 1 year, 27.4% at 2 years, 44.2% at 3 years, and 59.0% at 5 years. For patients with advanced ROS1-fusion NSCLC, the incidence of BM was 13.8% at 1 year, 27.4% at 2 years, and 52.3% at 3 years. The study concluded that BM are frequent in advanced ALK-rearranged or ROS1-fusion NSCLCs, with about 50% of patients having CNS involvement by three years of survival with targeted therapies. The data was compiled and analyzed from a cohort of 64 patients.

Asset Subtitle

Shaoyu Yang

Meta Tag

Speaker Shaoyu Yang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

brain metastases

ALK-rearranged

ROS1-fusion

non-small-cell lung cancer

NSCLC

China

advanced disease

cumulative incidence

living patients

targeted therapies